Kilitch Drugs India Ltd
NSE: KILITCH · Pharmaceuticals · sector
₹199.26NSE close 2026-10-26
Key numbers
Market cap₹697 cr
Price₹199.26
52w high / low₹268 / ₹117
P/E22.6xSector median 27.9x
P/B2.5xSector median 2.9x
Book value₹80.0
Dividend yield–Sector median 0.48%
ROE12.5%Sector median 11.7%
ROCE11.9%Sector median 12.3%
OPM15.3%Sector median 14.0%
Debt / equity0.32xSector median 0.16x
EV/EBITDA19.8xSector median 18.6x
Interest cover9.0x
Current ratio1.83x
Sales growth 3y+19.0%Sector median +9.6%
Profit growth 3y+42.4%Sector median +13.3%
PEG0.59x
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹69 cr vs borrowings ₹89 cr (FY26): borrowings are higher by ₹20 cr.
- Borrowings rose in each of the last 3 years (₹22 cr → ₹89 cr).
- Operating profit covered interest 9.0x in the last 12 months.
- No promoter shares are pledged.
- Operating cash flow was below net profit in 5 of the last 5 years (FY26, FY25, FY24, FY23, FY22).
- Revenue was higher than a year earlier in 3 of the last 4 quarters.
- Other income was 39% of net profit in the last 12 months.
- Debtor days went from 149 (FY24) to 186 (FY26).
- No dividend in the last 5 financial years.
- Price ₹199.26 on 2026-10-26: -25.6% from the 52-week high, +69.9% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹487.85 · low ₹131.27
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 47 | 56 | 61 | 43 | 49 | 54 | 90 | 45 |
| EBITDA | 6 | 9 | 15 | 3 | 5 | 6 | 22 | 3 |
| OPM % | 12.8% | 15.6% | 23.8% | 7.6% | 10.3% | 11.4% | 24.7% | 6.6% |
| Other income | 5 | 2 | 2 | 3 | 7 | 2 | 0 | 3 |
| Net profit | 9 | 6 | 10 | 3 | 8 | 4 | 15 | 3 |
| EPS (₹) | 2.68 | 1.85 | 3.23 | 0.94 | 2.48 | 1.25 | 4.24 | 0.83 |
| Revenue YoY | +3.1% | -4.2% | +46.3% | +4.0% | ||||
| Profit YoY | -5.0% | -25.7% | +39.6% | -4.0% |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 114 | 140 | 154 | 198 | 235 | 237 |
| EBITDA | 10 | 18 | 24 | 31 | 37 | 36 |
| Net profit | 7 | 10 | 15 | 27 | 30 | 30 |
| EPS (₹) | 2.37 | 3.35 | 4.58 | 8.30 | 8.91 | 8.80 |
| Revenue growth | +22.2% | +10.6% | +28.5% | +18.7% | +14.0% | |
| Profit growth | +41.8% | +39.7% | +82.9% | +13.0% | +7.3% | |
| Dividend / share (₹) | – | – | – | – | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +19.0% | +28.0% | +14.0% |
| Net profit | +42.4% | +52.4% | +7.3% |
| EPS | +38.5% | +49.7% | – |
| Share price | – | +11.9% (2y) | +8.6% |
Balance sheet
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Shareholders' equity | – | 152 | 176 | 202 | 280 |
| Borrowings | – | 22 | 32 | 49 | 89 |
| Cash & equivalents | – | 59 | 69 | 59 | 69 |
| Total assets | – | 220 | 240 | 313 | 458 |
| Fixed assets | – | 44 | 42 | 46 | 49 |
| Capital work in progress | – | 4 | 6 | 47 | 140 |
| Investments | – | 23 | 23 | 23 | 23 |
| Receivables | – | 54 | 63 | 85 | 120 |
| Inventory | – | 2 | 4 | 15 | 12 |
| Payables | – | 41 | 26 | 54 | 80 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash from operations | 6 | 3 | -0 | 18 | 24 |
| Cash from investing | -15 | 8 | -10 | -40 | -100 |
| Cash from financing | 7 | -1 | 9 | 13 | 82 |
| Capex | 8 | 4 | 0 | 0 | 100 |
| Free cash flow | -2 | -1 | -0 | 18 | -76 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ROE % | – | 6.9% | 8.3% | 13.2% | 10.8% |
| ROCE % | – | 9.7% | 12.2% | 15.7% | 12.0% |
| Debtor days | – | 142 | 149 | 156 | 186 |
| Inventory days | – | 10 | 18 | 53 | 33 |
| Payable days | – | 200 | 118 | 189 | 230 |
| Cash conversion cycle (days) | – | -48 | 49 | 20 | -11 |
| Working capital days | – | 150 | 193 | 165 | 156 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 63.77% |
| FIIs | 0.11% |
| DIIs | 0.50% |
| of which Mutual funds | 0.00% |
| of which Insurance | 0.00% |
| Government | 0.00% |
| Public (non-institutions) | 35.62% |
| Quarter | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 69.23% | 69.23% | 69.23% | 63.77% | 63.77% | 63.77% | 63.77% | 63.77% |
| Promoter group | % |
|---|---|
| Kilitch Company (Pharma) Limited | 37.92% |
| Bhavin Mukund Mehta | 14.43% |
| Mukund Mehta | 6.61% |
| Mira Bhavin Mehta | 4.81% |
| Public holders above 1% | % |
|---|---|
| Dipak Kanayalal Shah | 3.15% |
| Investor Education and Protection Fund Authority Ministry of Corporate Affairs | 2.29% |
| Mukul Mahavir Agrawal | 1.34% |
| Premilaben Rameshchandra Shah | 1.14% |
12,319 shareholders. Pledged: 0.00% of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| KILITCH | ₹697 cr | 22.6x | 2.5x | 12.5% | 11.9% | 15.3% | +19.0% | – |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2026-03-24 | Bonus | Bonus 1:1 |
| 2025-07-15 | Rights | Rights 2:23 @ Premium Rs 347/- |
| 2024-09-19 | Other | Annual General Meeting |
| 2023-09-21 | Other | Annual General Meeting |
| 2022-09-20 | Other | Annual General Meeting |
| 2021-09-21 | Other | Annual General Meeting |
| 2020-09-22 | Other | Annual General Meeting |
| 2019-09-20 | Dividend | Annual General Meeting/Dividend - Rs 0.5 Per Share |
| 2018-09-18 | Dividend | Annual General Meeting/Dividend Re 0.50 Per Share |
| 2017-09-20 | Other | Annual General Meeting |
| 2016-09-21 | Other | Annual General Meeting |
| 2015-09-21 | Other | Annual General Meeting |
| 2014-09-23 | Other | Annual General Meeting |
| 2013-09-24 | Other | Annual General Meeting |
| 2012-09-24 | Dividend | Special Interim Dividend Rs.30/- Per Share |
| 2011-08-18 | Dividend | Annual General Meeting And Dividend Re.1/- Per Share |
| 2010-10-14 | Dividend | Dividend-Re.1/- Per Share |
Documents
- Annual report FY26
- Annual report FY25
- Annual report FY24
- Annual report FY23
- Annual report FY22
- Announcements NSE filings
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | KILITCH |
| BSE code | 524500 |
| ISIN | INE729D01010 |
| Face value | ₹10.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-23 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.